5α-reductase is a membrane-bound enzyme that irreversibly converts testosterone to dihydrotestosterone (DHT), the most potent naturally occurring androgen with 2-5 times greater affinity for androgen receptors. This peripheral tissue conversion acts as a local hormone amplifier, occurring primarily in prostate, skin, hair follicles, liver, and genital tissues. Two isoenzymes exist: Type 1 (SRD5A1, predominant in skin and liver) and Type 2 (SRD5A2, concentrated in prostate and genital skin), each with distinct tissue distributions and regulation patterns.
Think of 5α-reductase as a turbocharger installed at each local factory rather than the main power plant. Your testes produce regular testosterone (the base fuel), which travels through the bloodstream to various tissues. But at certain locations—the prostate, scalp hair follicles, facial skin—there's a specialized turbocharger (5α-reductase) that converts this regular fuel into a supercharged version (DHT) that's 3-5 times more powerful. This local amplification system explains why two men with identical blood testosterone levels can have vastly different responses: one grows a thick beard and loses scalp hair (high 5α-reductase activity in those tissues), while the other keeps his hair but has a thin beard (lower enzyme activity). The problem arises when metabolic dysfunction—like a poorly maintained industrial facility with inflammation and insulin resistance—causes these turbochargers to work overtime, creating excess DHT that drives prostate overgrowth (BPH), acne, male pattern baldness, and unwanted facial hair in women. The turbochargers themselves become hypersensitive to inflammatory signals, creating a vicious cycle where metabolic chaos amplifies androgen effects at the tissue level, independent of what's happening in the bloodstream.
5α-reductase catalyzes the NADPH-dependent reduction of the Δ4,5 double bond in testosterone to produce 5α-dihydrotestosterone:
Testosterone + NADPH + H⁺ → DHT + NADP⁺
graph TD
A[Testosterone in circulation] --> B{5α-reductase Type 1 or Type 2}
B --> C[DHT production]
C --> D[Androgen Receptor binding]
D --> E[AR-DHT complex nuclear translocation]
E --> F[Androgen Response Element activation]
F --> G[Gene transcription]
H[Insulin Resistance] --> I["↑ NF-κB activation"]
I --> J["↑ 5α-reductase expression"]
K[Chronic Inflammation] --> I
L[Obesity/Adipose tissue] --> M["↑ Inflammatory cytokines"]
M --> I
N[Metabolic Health] --> O["↓ Enzyme activity"]
P[Zinc sufficiency] --> O
Q[Saw palmetto/Phytosterols] --> O
style C fill:#ff9999
style I fill:#ffcc99
style O fill:#99ff99
Detailed molecular cascade:
-
Enzyme structure and isoforms:
- Type 1 (SRD5A1): pH optimum 6.0-8.5, predominantly liver, skin (sebaceous glands), scalp
- Type 2 (SRD5A2): pH optimum 5.0-5.5, predominantly prostate, epididymis, seminal vesicles, genital skin
- Both require NADPH as cofactor and are membrane-bound to endoplasmic reticulum
-
Conversion pathway:
- Testosterone enters target tissue via passive diffusion or SHBG-mediated delivery
- 5α-reductase reduces C4-C5 double bond → produces 5α-dihydrotestosterone
- DHT has 2-5x higher affinity for androgen receptor (AR) than testosterone
- DHT-AR binding induces more stable receptor conformation → stronger transcriptional activity
- DHT cannot be aromatized to estrogen (lacks required double bond) → pure androgenic signal
-
Transcriptional effects:
- DHT-AR complex → nuclear translocation → binds Androgen Response Elements (ARE)
- In prostate: activates genes for epithelial proliferation, PSA production, growth factors
- In hair follicles: miniaturizes follicles (androgenic alopecia) via TGF-β1 upregulation
- In sebaceous glands: increases sebum production via lipogenic gene expression
-
Inflammatory upregulation:
-
Inactivation:
- DHT → 3α-androstanediol (via 3α-hydroxysteroid dehydrogenase) → less active metabolite
- DHT → 3β-androstanediol (via 3β-hydroxysteroid dehydrogenase) → weakly androgenic
- Both metabolites conjugated and excreted
Pattern recognition for cPNI practitioners:
The 5α-reductase system exemplifies peripheral hormone amplification gone wrong under metabolic stress—a key concept in understanding why systemic hormone levels don't always predict tissue-level effects. This enzyme system connects directly to multiple selfish systems and evolutionary mismatches:
Selfish immune and metabolic system convergence: Chronic inflammation from metabolic syndrome, insulin resistance, or gut dysbiosis drives inflammatory transcription factors (NF-κB, STAT3) that upregulate 5α-reductase expression in peripheral tissues. This creates a feed-forward loop: metabolic dysfunction → inflammation → excess DHT → further metabolic disruption (DHT impairs insulin signaling and promotes visceral adiposity). The selfish immune system prioritizes inflammatory responses that inadvertently amplify androgen pathways, explaining why metabolically unhealthy patients develop androgen-excess phenotypes despite normal serum testosterone.
Clinical presentations:
-
Benign Prostatic Hyperplasia (BPH):
- Driven by excess Type 2 5α-reductase activity in prostate epithelium
- Symptoms: urinary frequency, urgency, nocturia, weak stream, incomplete emptying
- DHT drives prostate cell proliferation via EGFR and IGF-1 receptor pathways
- Intervention priority: Address metabolic root causes before pharmaceutical inhibition
- PSA monitoring (normal <4 ng/mL, but context-dependent)
-
Androgenic alopecia (male and female pattern baldness):
- Type 1 5α-reductase in scalp hair follicles produces local DHT
- DHT miniaturizes hair follicles via prolonged telogen phase and shortened anagen phase
- Women with PCOS or insulin resistance particularly susceptible
- Hamilton-Norwood scale (men) or Ludwig scale (women) for grading
-
Acne vulgaris:
- Type 1 5α-reductase in sebaceous glands increases sebum production
- DHT → lipogenic gene expression → comedone formation → Propionibacterium acnes proliferation
- Worsens with high-glycemic diets, dairy intake (IGF-1 stimulation), chronic stress
-
Hirsutism in women:
-
Gender-affirming care considerations:
- Trans women: 5α-reductase inhibitors adjunct to estrogen therapy
- Cis men seeking feminization: strategic inhibition while monitoring mood effects
Evolutionary mismatch context:
Our ancestral environment featured low insulin resistance (no refined carbohydrates), higher physical activity (better insulin sensitivity), and lower chronic inflammatory burden. Modern sedentary lifestyle with processed foods creates sustained NF-κB activation and insulin resistance—conditions under which 5α-reductase becomes dysregulated. This enzyme system, evolved for appropriate androgenic responses in metabolically healthy individuals, becomes pathological under chronic metabolic stress—a classic mismatch disease mechanism.
Intervention hierarchy (cPNI approach):
-
Metabolic restoration (primary):
-
Targeted nutritional inhibition:
- Zinc 30-50mg/day (competitive Type 1 and Type 2 inhibitor, exam fact: plasma zinc <70 μg/dL associated with higher enzyme activity)
- Saw-palmetto (Serenoa repens) 320mg/day standardized extract (85-95% fatty acids and sterols): competitive inhibition, comparable efficacy to finasteride 5mg in mild-moderate BPH
- Green tea catechins (EGCG) 400-800mg/day: inhibits both isoforms
- Pumpkin seed oil (Cucurbita pepo) 1000mg/day: contains Δ7-sterols that inhibit enzyme
- Stinging nettle root (Urtica dioica): blocks DHT binding to SHBG, reducing free DHT
- Advantage: Addresses enzyme activity without complete androgen blockade
-
Pharmaceutical inhibition (when necessary):
- Finasteride 1mg (Type 2 selective) or 5mg (for BPH): 60-70% reduction in serum DHT
- Dutasteride 0.5mg (dual Type 1 and Type 2 inhibitor): 90% reduction in serum DHT
- Warning (exam critical): Post-finasteride syndrome documented in subset of patients—persistent sexual dysfunction (reduced libido, erectile dysfunction), depression, cognitive impairment, even after discontinuation. Mechanism debated but may involve neurosteroid disruption (DHT is precursor to 3α-androstanediol, a neurosteroid).
- Clinical judgment: Metabolic restoration + nutritional inhibitors preferred first-line; pharmaceuticals reserved for severe cases or when natural approaches insufficient
Threshold values:
- Serum DHT: Normal adult male 30-85 ng/dL (women 4-22 ng/dL)
- DHT:testosterone ratio: normally 1:10 (higher ratio suggests increased 5α-reductase activity)
- Salivary DHT testing available for tissue-level assessment
- Free androgen index (FAI): (Total testosterone ÷ SHBG) × 100; >5 in women suggests hyperandrogenism
- Two isoenzymes: Type 1 (SRD5A1, skin/liver/scalp) and Type 2 (SRD5A2, prostate/genital tissue), each with distinct pH optima and tissue distribution
- DHT is 2-5x more potent than testosterone at androgen receptor due to higher binding affinity and slower dissociation rate (half-life at AR: DHT ~40 min vs testosterone ~20 min)
- Cannot be aromatized: DHT lacks the C4-C5 double bond required for aromatase activity, making it a pure androgenic signal (unlike testosterone which can convert to estradiol)
- NADPH-dependent reaction: Enzyme requires NADPH as cofactor, linking androgenic activity to cellular redox state and pentose phosphate pathway activity
- Inflammation amplifies activity: NF-κB activation directly upregulates SRD5A1 and SRD5A2 gene transcription; IL-6 >10 pg/mL and TNF-α >8 pg/mL correlate with increased enzyme expression
- Insulin resistance connection: Hyperinsulinemia (fasting insulin >15 μIU/mL) increases 5α-reductase activity via PI3K-Akt pathway activation of steroidogenic enzymes
- Zinc is natural inhibitor: Plasma zinc <70 μg/dL associated with increased enzyme activity; supplementation 30-50mg/day provides competitive inhibition (exam fact: zinc competes with testosterone at enzyme active site)
- Saw palmetto efficacy: 320mg/day standardized extract shows 38% improvement in urinary flow rate in BPH, comparable to finasteride 5mg with fewer sexual side effects (multiple RCTs)
- Post-finasteride syndrome: Documented in ~2-4% of users—persistent sexual dysfunction, depression, cognitive changes even after discontinuation; mechanism involves neurosteroid disruption
- Type 2 deficiency syndrome: Genetic SRD5A2 mutations cause 5α-reductase deficiency—46,XY individuals born with ambiguous/female-appearing genitalia, virilization at puberty (demonstrates critical developmental role)
- Serum DHT normal ranges: Adult males 30-85 ng/dL, adult females 4-22 ng/dL; ratio of DHT:testosterone normally 1:10 (higher ratio indicates increased enzyme activity)
- BPH prevalence: 50% of men age 50, 90% by age 85—strongly correlated with metabolic syndrome components (waist circumference >102cm, fasting glucose >100mg/dL, triglycerides >150mg/dL)
- Testosterone — substrate for 5α-reductase; converted to more potent DHT in peripheral tissues
- dihydrotestosterone — product of 5α-reductase reaction; 2-5x more potent androgen driving tissue-level effects
- androgen receptor — DHT has higher affinity and slower dissociation rate than testosterone, producing stronger transcriptional activation
- Insulin resistance — upregulates 5α-reductase expression via PI3K-Akt pathway and inflammatory transcription factors; fasting insulin >15 μIU/mL associated with increased enzyme activity
- NF-κB — inflammatory transcription factor that directly upregulates SRD5A1 and SRD5A2 gene expression; links chronic inflammation to androgen amplification
- Metabolic syndrome — all components (central obesity, insulin resistance, dyslipidemia, hypertension) independently increase 5α-reductase activity
- Chronic inflammation — cytokines IL-6 and TNF-α activate JAK-STAT pathways that increase enzyme transcription
- PCOS — polycystic ovary syndrome characterized by hyperandrogenism often driven by increased peripheral 5α-reductase activity in women
- Obesity — adipose tissue inflammation produces sustained cytokine release that chronically elevates enzyme expression; visceral fat particularly problematic
- Acne — sebaceous gland 5α-reductase (Type 1) converts testosterone to DHT, driving lipogenesis and sebum overproduction
- aromatase — contrasting enzyme that converts testosterone to estradiol; DHT cannot be aromatized, making it pure androgenic signal
- Zinc — natural competitive inhibitor of both 5α-reductase isoforms; plasma levels <70 μg/dL correlate with increased enzyme activity
- saw-palmetto — Serenoa repens extract contains fatty acids and phytosterols that competitively inhibit 5α-reductase; 320mg/day effective for mild-moderate BPH
- EGCG — green tea catechin that inhibits both Type 1 and Type 2 isoforms; 400-800mg/day therapeutic range
- IGF-1 — insulin-like growth factor elevated by dairy consumption and high glycemic diets; stimulates sebaceous 5α-reductase activity driving acne
- Gut dysbiosis — impaired barrier function increases LPS translocation, activating TLR4-NF-κB inflammatory cascade that upregulates enzyme
- Prostate cancer — while BPH is DHT-driven, relationship to prostate cancer complex; some evidence 5α-reductase inhibitors reduce cancer risk
- Hair follicles — scalp Type 1 5α-reductase produces DHT that miniaturizes follicles in androgenic alopecia pattern
- NADPH — required cofactor for 5α-reductase reaction; links enzyme activity to pentose phosphate pathway and cellular redox state
- Pregnenolone — steroid hormone precursor; chronic stress and cortisol production steal pregnenolone from androgen pathways, but local 5α-reductase still amplifies whatever testosterone reaches tissues
- Neurosteroids — DHT is precursor to 3α-androstanediol (neurosteroid); finasteride inhibition disrupts neurosteroid production, potentially explaining mood/cognitive side effects
- Type 2 Diabetes — hyperglycemia and hyperinsulinemia create perfect storm for 5α-reductase upregulation; HbA1c >6.5% associated with increased enzyme activity
- COX-2 — cyclooxygenase-2 inflammation marker; elevated COX-2 activity correlates with increased 5α-reductase expression in prostate tissue
- Cortisol — chronic elevation from stress indirectly affects 5α-reductase via insulin resistance and inflammatory pathways
- Module 7 (Endocrine and Metabolic Systems)